iv/oiriMi CMiiTiLjwiAi ikiM 1 1 
Principal Invejligaior/Pfogram Director (List, first, middle): 
• Taha M, Ordoner NG, Kulkarnl S, Owen H, Ro JS, Eortobagyi O, Reading CL, Dicke 
KA, Spitzer C: A monoclonal antibody cocktail for detection of microffletastatic 
tumor celle in the bone marrow of breast cancer patients. Bone Harrow Transplant 
4:297-303, 1989. 
• Hortobagryi O, Hug V, Buzdar A, Holmes F, Fritsche H: Sequential cyclic combined 
hormonal therapy for metastatic breast cancer. Cancer 64:1002-1006, 1989. 
• Patel H2, Buzdar AU, Bortobagyi ON: Role of adjuvant chemotherapy in male breast 
cancer. Cancer 64:1583-1585, 1989. 
• Ang FT, Buzdar AU, Smith TL, Xau S, HortobagYi ON: Analysis of dose intensity 
in doxorubicin-containing adjuvant chemotherapy in stage II and III breast 
cancer. J Clin Oncol 7:1677-1684, 1989. 
• Ro J, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini C, Fritsche H, Bortobagyi 
0: c-erbB-2 Amplification in Node-negative Human Breast Cancer. Cancer Res 
49:6941-6944, 1989. 
• Sneige N, White VA, Katz RL, Troncoso P, Libshitz HI, Bortobagyi CN: Ductal 
Carcinoma-.in-situ of. the breast: Fine-needle aspiration cytology of 12 cases. 
Diagn Cytopathol 5:371-377, 1989. 
• Koh EH, Ro JS, Wildrick DM, Bor-tobagyi GN, Blick M: Analysis of estrogen 
receptor gene structure in breast cancer. Anticancer Res 9 ( 6) : 1841-1845, 1989. 
• Buzdar AU, KcKeese KD, Bortobagyi GN, Smith TL, Kau S, Fraschini G, Bug V, 
Ellerbroek N, Holmes FA, Ames F, Singletary SE: Is chemotherapy effective in 
reducing the local failure rate in patients with operable breast cancer? Cancer 
65:394-399, 1990. 
•Sutton R, Buzdar AU, Bortobagyi ON: .Pregnancy and offspring after adjuvant 
chemotherapy in breast cancer patients. Cancer 65:847-850, 1990. 
•Holmes FA, Fritsche HA, Loewy JW, GeitneT AM, Sutton RC, Buzdar AU, Bortobagyi 
CN: Measurement of estrogen and progesterone receptors in human breast tumorst 
Enzyme immunoassay versus binding assay. J Clin Oncol 8:1025-1035, 1990. 
•Dunphy FR, Spitzer C, Buzdar AU, Bortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, 
Jagganath S, Holmes F, Wallerstein RO, Bohannan PA, Dicke KA: Treatment of 
estrogen receptor-negative breast cancer with double high-dose chemotherapy 
intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990. 
•Bortobagyi CN: Comprehensive management of locally advanced breast cancer. 
; Cancer 66(Suppl. ) :1387-1391, 1990. 
» •Ro JS, Sahin A, Ro JY, Fritsche H, Bortobagyi O, Blick M: Immunohistochemical 
Analysis of p^-Clycoprotein Expression Correlated With Chemotherapy Resistance in 
* Locally Advanced Breast Cancer. Hum Pathol 21:787-791, 1990. 
C «Sahin A, Ro JS, Ro JY, Blick M, El-Naggar AX, Ordonez NC, Fritsche KA, Smith TL, 
* Bortobagyi ON, Ayala AG: Ki-67 immunostaining in node-negative stage 1/11 breast 
) carcinoma: significant correlation with prognosis. Cancer 68:549-557, 1991. 
, •Ziegler LD, Connelly JH, Frye D, Smith TL, Boz-tobagyi GN: Lack of correlation 
J between histologic findings and response to chemotherapy in metastatic breast 
. cancer. Cancer 68:628-634, 1991. 
I •Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RA, 
* Bortobagyi GN: Evaluation of Three Oral Dosages of Ondansetron in the Prevention 
. of Nausea and Emesis Associated With Cyclophosphamide-Doxorubicin Chemotherapy. 
. J Clin Oncol 9:1268-1274, 1991. 
•Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber KN, Buzdar 
I AU, Frye DK, Bortobagyi ON: Phase II Trial of Taxol, an Active Drug in the 
Treatment of Metastatic Breast Cancer. J Natl Cancer Inst 83:1797-1805, 1991. 
• Huan SD, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Sp>encer V, LeMaistre CF, 
Deisseroth AB, Bortobagyi ON, Holmes FA, Andersson BS, Spitzer G: Impact of 
1 ’ Autologous Bona Marrow Infusion on Heroatop>oietic Recovery .After High-Dose 
Cyclophosphamide, £top>oside, and Cisplatin. J Clin Oncol 9:1609-1617, 1991. 
• Buzdar AD, Kau SW, Bortobagyi ON, Ames FC, Holmes FA, Fraschini G, Hug V, 
Theriault RL, KcNeese KD, Singletary SE: Clinical Course of Patients With Breast 
Cancer With Ten or More Positive Nodes Who Were Treated With Doxorubicin- 
Containing Adjuvant Therapy. Cancer 69:448-452, 1992. 
• Jaiyesimi lA, Buzdar AU, Bortobagyi O: • Inflammatory Breast Cancer: A Review. 
J Clin Oncol 10:1014-1024, 1992. 
•Buzdar AU, Bortobagyi ON, Kau SW, Smith TL, Fraschini G, Holmes FA, Cutterman 
JU, Hug VM, Singletary SE, Ames FC, McNeese MD: Adjuvant Therapy with Escalating 
Doses of Doxorubicin and Cyclophosphamide with or without Leukocyte a-interferon 
for Stage II or III Breast Cancer. J Clin Oncol 10:1540-1546, 1992. 
•Dhingra K, Sahin A, Supak J, Kim SY, Bortobagyi O, Hittelman WN: Chromosome in 
situ Hybridization on Formalin-Fixed Mammary Tissue Using Non-I sotopic, Non- 
fluoreacent Probes: Technical Considerations and Biologic Implications. Braaat 
Cancer Rce Treat 23:201-210, 1992. 
Recombinant DNA Research, Volume 19 
[ 548 ] 
